<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147666</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-040</org_study_id>
    <nct_id>NCT01147666</nct_id>
  </id_info>
  <brief_title>Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining&#xD;
      and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease(ESRD)on&#xD;
      maintenance hemodialysis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose ranging study with consecutive cohorts in two subject populations: patients normally&#xD;
      responding to current anemia treatment (epoetin alfa) (&quot;normoresponders&quot;) and patients not&#xD;
      responding well to current treatment (&quot;hyporesponders&quot;). Normoresponders are randomized to&#xD;
      study drug FG-4592 or epoetin alfa; hyporesponders are randomized to study drug FG-4592 or&#xD;
      epoetin alfa or placebo. The study objectives are to demonstrate that FG-4592 is effective in&#xD;
      maintaining hemoglobin (Hb) levels when converting from epoetin alfa and to establish optimum&#xD;
      starting doses and dose adjustment regimens for Hb maintenance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin maintenance using various FG-4592 dosing regimens</measure>
    <time_frame>week 6 and 17-20</time_frame>
    <description>Outcome measure 1: Number (%) of subjects with hemoglobin levels at Week 6 within -0.5 g/dL from baseline&#xD;
Outcome measure 2: Number (%) of subjects with hemoglobin greater than or equal to 11 g/dL at Weeks 17, 18, 19 and 20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate dose adjustments to maintain hemoglobin in ESRD patients</measure>
    <time_frame>6 weeks; 19 weeks</time_frame>
    <description>Outcome measure: Number of dose adjustments required during the dosing period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate pharmacokinetic and pharmacodynamic parameters</measure>
    <time_frame>19 weeks</time_frame>
    <description>Outcome measure 1: trough plasma FG-4592 concentration at week 1, 4 and 6 in all subjects&#xD;
Outcome measure 2: plasma FG-4592 concentration and EPO concentration at various hours after dosing in a subset of subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Population A; Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients responding normally to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population A; Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients responding normally to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Different dose levels</description>
    <arm_group_label>Population A; Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Per current label instruction</description>
    <arm_group_label>Population A; Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Different dose levels</description>
    <arm_group_label>Population B; Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive capsules matching appearance of FG-4592 capsules</description>
    <arm_group_label>Population B; Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Per current label instruction</description>
    <arm_group_label>Population B; Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years&#xD;
&#xD;
          2. End-stage renal disease (ESRD) and receiving maintenance hemodialysis&#xD;
&#xD;
          3. Two most recent hemoglobin values obtained during screening period must be within the&#xD;
             ranges set below:&#xD;
&#xD;
               -  Croup A. Normoresponder Criteria: Hb range in the 8 weeks prior to randomization&#xD;
                  within 9.0 to 13.5 g/dL&#xD;
&#xD;
               -  Group B. Hyporesponder Criteria: Hb range in the 8 weeks prior to randomization&#xD;
                  within 8.5 to 13.5 g/dL&#xD;
&#xD;
          4. Epoetin alfa, dose requirements:&#xD;
&#xD;
               -  Group A. Normoresponder Criteria - Cohorts A-1 to A-12: Stable IV epoetin alfa&#xD;
                  dose at baseline (i.e., no more than a 30% fluctuation in the weekly dose) during&#xD;
                  the 4 weeks prior to study Day -3&#xD;
&#xD;
                    -  Cohorts A-1 to A-4: Current and previous (past 4 weeks) epoetin alfa dose&#xD;
                       range 25 to 85 IU/kg/dose, three times a week (TIW); weekly dose between 75&#xD;
                       and 255 IU/kg/week&#xD;
&#xD;
                    -  Cohort A-5: Current and previous (past 4 weeks) epoetin alfa dose range&#xD;
                       =/&gt;85 to 115 IU/kg/dose, TIW; total weekly dose between 255 and 335&#xD;
                       IU/kg/week&#xD;
&#xD;
                    -  Cohort A-9: Current and previous (past 4 weeks) epoetin alfa dose range&#xD;
                       =/&gt;85 to 150 IU/kg/dose, TIW; total weekly dose between 255 and 450&#xD;
                       IU/kg/week&#xD;
&#xD;
                    -  Cohorts A-6 to A-8: Current and previous (past 4 weeks) epoetin alfa dose&#xD;
                       range 25 to 115 IU/kg/dose, TIW, and two times a week (BIW); total weekly&#xD;
                       dose between 75 and 345 IU/kg/week&#xD;
&#xD;
                    -  Cohorts A-10 to A-12: Optional cohorts TBD, dosing frequency and dose range&#xD;
                       to be determined by sponsor&#xD;
&#xD;
               -  Group B. Hyporesponder Criteria:&#xD;
&#xD;
                    -  Cohort B-1 (completed): Current and previous (past 4 weeks) epoetin alfa&#xD;
                       dose range 125 to 400 IU/kg/dose, TIW; weekly dose between 375 and 1200&#xD;
                       IU/kg/week&#xD;
&#xD;
                    -  Cohort B-2 to B-4: Current and previous (past 4 weeks) epoetin alfa dose&#xD;
                       range &gt;115 IU/kg/dose, TIW; total weekly dose &gt;345 IU/kg/week no requirement&#xD;
                       for stability of epoetin alfa doses&#xD;
&#xD;
          5. Complete Blood Count (CBC), Hematology, liver function blood tests, serum folate and&#xD;
             vitamin B12 within acceptable limits&#xD;
&#xD;
          6. Absence of active or chronic gastrointestinal bleeding&#xD;
&#xD;
          7. hsCRP &lt;60 mg/L for normoresponders Cohorts A-8 through A-12 enrolled under Amendment&#xD;
             3; no hsCRP criteria for hyporesponders&#xD;
&#xD;
          8. Body weight: 40 to 140 kg (dry weight)&#xD;
&#xD;
          9. Body mass index (BMI): 18 to 45 kg/m2&#xD;
&#xD;
         10. Dialysis vascular access via native arteriovenous fistula or synthetic graft, or&#xD;
             permanent (tunneled) catheter (not via temporary catheter); permanent and temporary&#xD;
             catheters, however, are still prohibited in Cohort A-5&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Anticipated change in hemodialysis prescription&#xD;
&#xD;
          2. Any clinically significant infection or evidence of an underlying infection&#xD;
&#xD;
          3. Positive for any of the following: Human immunodeficiency virus (HIV); hepatitis B&#xD;
             surface antigen (HBsAg); or anti-hepatitis C virus antibody (anti-HCV Ab)&#xD;
&#xD;
          4. History of chronic liver disease&#xD;
&#xD;
          5. New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          6. Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus&#xD;
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in&#xD;
             remission&#xD;
&#xD;
          7. History of myelodysplastic syndrome&#xD;
&#xD;
          8. History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric&#xD;
&#xD;
          9. Active hemolysis or diagnosis of hemolytic syndrome&#xD;
&#xD;
         10. Known bone marrow fibrosis&#xD;
&#xD;
         11. Uncontrolled or symptomatic secondary hyperparathyroidism&#xD;
&#xD;
         12. Any prior organ transplantation&#xD;
&#xD;
         13. Drug-treated gastroparesis or short-bowel syndrome&#xD;
&#xD;
         14. History of alcohol or drug abuse; or a positive drug screen for a substance that has&#xD;
             not been prescribed for the subject&#xD;
&#xD;
         15. Prior treatment with FG-4592&#xD;
&#xD;
         16. Diagnosis or suspicion of renal cell carcinoma&#xD;
&#xD;
         17. RBC transfusion within 12 weeks prior to Day 1, or anticipated need for RBC&#xD;
             transfusion during the dosing period&#xD;
&#xD;
         18. IV iron supplement within 2 weeks prior to Day 1 and/or unwilling to withhold IV iron&#xD;
             during the dosing/Treatment period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marietta Franco</last_name>
    <role>Study Director</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Renal</keyword>
  <keyword>Anemia</keyword>
  <keyword>Oral anemia treatment</keyword>
  <keyword>Hemoglobin levels</keyword>
  <keyword>Blood count</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Normoresponder</keyword>
  <keyword>Hyporesponder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 1, 2021</submitted>
    <returned>September 30, 2021</returned>
    <submitted>November 17, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

